Publication:

A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells

Loading...
Thumbnail Image

Date

2005

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

National Academy of Sciences
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Stegmeier, F., G. Hu, R. J. Rickles, G. J. Hannon, and S. J. Elledge. 2005. “A Lentiviral MicroRNA-Based System for Single-Copy Polymerase II-Regulated RNA Interference in Mammalian Cells.” Proceedings of the National Academy of Sciences102 (37): 13212–17. doi:10.1073/pnas.0506306102.

Abstract

The advent of RNA interference has led to the ability to interfere with gene expression and greatly expanded our ability to perform genetic screens in mammalian cells. The expression of short hairpin RNA (shRNA) from polymerase III promoters can be encoded in transgenes and used to produce small interfering RNAs that downregulate specific genes. In this study, we show that polymerase II-transcribed shRNAs display very efficient knockdown of gene expression when the shRNA is embedded in a microRNA context. Importantly, our shRNA expression system [called PRIME (potent RNA interference using microRNA expression) vectors] allows for the multicistronic cotranscription of a reporter gene, thereby facilitating the tracking of shRNA production in individual cells. Based on this system, we developed a series of lentiviral vectors that display tetracycline-responsive knockdown of gene expression at single copy. The high penetrance of these vectors will facilitate genomewide loss-of-function screens and is an important step toward using bar-coding strategies to follow loss of specific sequences in complex populations.

Description

Other Available Sources

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories